Rimeporide

Rimeporide

Clinical data
ATC code	none
Legal status
Legal status	Experimental
Identifiers
IUPAC name N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine
CAS Number	187870-78-6
PubChem (CID)	9799487
ChemSpider	7975252
UNII	QH6B4V5743
ChEMBL	CHEMBL2107802
Chemical and physical data
Formula	C11H15N3O5S2
Molar mass	333.38 g·mol^−1
3D model (Jmol)	Interactive image
SMILES Cc1cc(c(cc1C(=O)NC(=N)N)S(=O)(=O)C)S(=O)(=O)C
InChI InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15) Key:GROMEQPXDKRRIE-UHFFFAOYSA-N

Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation.^[1] it has been granted orphan drug status by the European Medicines Agency.^[2]

Mechanism of action

The substance blocks an ion pump called sodium–hydrogen antiporter 1 (NHE-1). While the exact mechanism is unknown, it is speculated that inhibition of this pump reduces sodium and calcium overload in cells of Duchenne patients.^[1]

History

Rimeporide was designed as a treatment for chronic heart failure. It was unsuccessful in Phase I clinical trials, but was tolerated well by volunteers. Subsequently, the drug was sold to EspeRare, a Swiss nonprofit organisation^[3] that aims at developing drugs for rare diseases. As of May 2015, the substance is in preclinical development for Duchenne.^[1]

See also

Other drugs for Duchenne muscular dystrophy

• Ataluren
• Biostrophin (experimental)
• Idebenone (experimental)

References

1. Spreitzer, Helmut (26 May 2015). "Neue Wirkstoffe – Rimeporid". Österreichische Apothekerzeitung (in German). 69 (11): 12.
2. "EspeRare's Rimeporide receives Orphan Drug Designation in Duchenne Muscular Dystrophy". EspeRare. 4 May 2015.
3. "Our mission and vision". EspeRare. Retrieved 23 July 2015.